Dogan, B. A. Et Al. 2016. Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma. ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS , vol.16, no.1 , 47-55.

Dogan, B. A., Arduc, A., Tuna, M. M., Berker, D., Demirci, N., Demirtas, S., ... Cicekcioglu, H.(2016). Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma. ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS , vol.16, no.1, 47-55.

Dogan, Bercem Et Al. "Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma," ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS , vol.16, no.1, 47-55, 2016

Dogan, Bercem A. Et Al. "Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma." ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS , vol.16, no.1, pp.47-55, 2016

Dogan, B. A. Et Al. (2016) . "Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma." ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS , vol.16, no.1, pp.47-55.

@article{article, author={Bercem Aycicek Dogan Et Al. }, title={Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma}, journal={ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS}, year=2016, pages={47-55} }